Sherif Riad reported grant involving 88,000 derivative units of OCULAR THERAPEUTIX, INC at $0.00 for $0 on Nov 6, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 10, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
88,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
88,000Direct
Trade date
Nov 6, 2026Grant
Filed
Nov 10, 2026, 4:10 PM ET4-day reporting delay
Accession
0001104659-26-125172Code A · Transaction 396952
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 6, 2026Grant28,000$0.00$0Trade 396951
2 transaction rows in this filing. Joint filers share the same rows.

OCUL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
OCUL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +5.5%1w ago +1.8%1d ago −6.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 6, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant. F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.